partnering to advance global health - sanofi€¦ · digital page 13 gem general medicines &...
TRANSCRIPT
PARTNERING TO ADVANCE GLOBAL HEALTH
Contents
Partnering with UsPartnering: Sharing Expertise to Drive Innovation
page 1
Sanofi at a GlanceSanofi, a Global Healthcare Leader
page 2
Strategic PrioritiesStrategy 2015-2020
page 3
Diabetes & CardiovascularDiabetes
page 4
Cardiovascular
page 5
Sanofi GenzymeRare Diseases
page 6
Multiple Sclerosis & Neuroscience
page 7
Immunology
page 8
Oncology
page 9
Sanofi PasteurVaccines
page 10
Infectious DiseasesInfectious Diseases
page 11
PlatformsDrug Discovery & Biologics
page 12
Digital
page 13
GEMGeneral Medicines & Emerging Markets
page 14
CHCConsumer Healthcare
page 15
Partnering ModelPartnering Capabilities
page 16
Alliance ManagementValue Creation Through Partnerships
page 18
Partnering Opportunities Contacts
page 20
1 — PARTNERING WITH SANOFI
Partnering with Us
Partnering: Sharing Expertise to Drive Innovation
“Our organization is made up of many talented
individuals with varied skills and experiences.
Most importantly, everyone has a deep
commitment to making Sanofi one of the best
pharmaceutical companies in the industry.
We all want to bring important medicines
to patients in need, all over the world.
This is core to what we do and think about.”
Muzammil Mansuri Executive Vice-President Strategy & Business Development
We are a global life sciences company committed to improving access to
healthcare and supporting the people we serve throughout the continuum of care.
From prevention to treatment we transform scientific innovation into healthcare
solutions in human Vaccines, Rare Diseases, Multiple Sclerosis & Neuroscience,
Oncology, Immunology, Infectious Diseases, Diabetes & Cardiovascular and
Consumer Healthcare. Our diversity and global reach is supported by our strong
presence in Mature and Emerging Markets.
Business Development is a key component of our strategy. In order to bring
life-changing treatments to unmet healthcare challenges, we will always pursue
innovation. We continuously seek innovative collaborations to build alliances
that create value for global health.
Collaborations are, for us, one of the crucial elements of success. We are committed
to share our skills and projects with the best professionals and companies in each
of our areas of interest, wherever they are. We have signed agreements with partners
around the world, strengthening our network of innovation excellence to deliver
great quality products.
All activities critical to Business Development have been brought together into
one global, integrated group. We are on a journey dedicated to make a difference
on people’s daily life, wherever they live and enable them to enjoy a healthier life.
We invite you to join us on this exciting and worthwhile endeavor to offer innovative
solutions that protect health, enhance people’s quality of life and improve access
to healthcare around the world.
2 — PARTNERING WITH SANOFI
Sanofi at a Glance
SANOFI, a Global Healthcare Leader committed to preventing and
treating diseases around the world
+100,000employees in more
than 100 countries
6key innovations
between 2015-2020
Health solutions
available in
+170 countries
5.2 billion invested in R&D
in 2016
Pharmaceuticals
86.5%€29,244 M
Vaccines
13.5%€4,577 M
Europe(2)
25.7%€8,679 M
United States
36.6%€12,391 M
Emerging markets(3)
28.4%€9,593 M
Rest of the world(4)
9.3%€3,158 M
Company sales
by activities(1)
Company sales
by geographical areas(1)
€33.8 Bn company sales(1)
(1) Following the closing of the business swap with Boehringer Ingelheim, which consisted of an exchange of Sanofi’s Animal
Health business and BI’s Consumer Healthcare business, those figures are presented excluding Animal Health business.
(2) Western Europe + Eastern Europe (except Eurasia).
(3) World excluding U.S., Canada, Western & Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand
and Puerto Rico.
(4) Japan, Canada, South Korea, Australia, New Zealand, Puerto Rico.
3 — PARTNERING WITH SANOFI
Strategic Priorities
Strategy 2015-2020
Our 5 Global Business
Units
Sanofi GenzymeRARE DISEASES MULTIPLE SCLEROSIS & NEUROSCIENCE IMMUNOLOGY ONCOLOGY
Sanofi PasteurVACCINES
General Medicine & Emerging MarketsGENERICS MATURE PRODUCTS
Consumer Healthcare
Diabetes & Cardiovascular
1. RESHAPE THE PORTFOLIORestructure our portfolio to focus
on human health• Sustain leadership and consolidate operations
in areas where Sanofi has substantial expertise
and experience: Diabetes & Cardiovascular,
Vaccines, Rare Diseases, and Emerging Markets
• Build competitive positions and develop
expertise in Multiple Sclerosis & Neuroscience,
Oncology and Immunology
• Position Sanofi as a leader in Consumer
Healthcare
3. SUSTAIN INNOVATION IN R&DEnhance R&D innovation to develop
our drugs and vaccines• Products that make a real difference to the
doctors writing prescriptions, payers reimbursing
their cost, and the patients who should,
ultimately, receive the best possible care
• Devote substantial resources to the most
promising projects in our R&D portfolio
• Foster existing R&D collaborations and
increase capacity for external innovation
2. DELIVER OUTSTANDING LAUNCHESSuccessfully launch our major
new products• Innovation driven by new medicines, such
as Toujeo®, Praluent®, and Dengvaxia®
• Prepare the introduction of the insulin glargine/
lixisenatide combination SoliquaTM/SuliquaTM
for diabetes, Dupixent® for atopic dermatitis,
and Kevzara® for rheumatoid arthritis
4. SIMPLIFY THE ORGANIZATIONStreamline and simplify
our organization teams• Establish five global business units to improve
collaboration between R&D and business
operations, thereby fast-tracking the time to
market for our innovations
• Globalize and integrate all key functions
including Research & Development
and Strategy & Business Development
4 — PARTNERING WITH SANOFI
Diabetes & Cardiovascular
DiabetesWe are a global leader in Diabetes due to our rich
history and pipeline and our ambition is to expand
care to the next level.
Our teams are focused on developing treatments
that will alter the progression of cardio-metabolic
disease and reduce the risk of debilitating
complications that are challenging for individuals
and healthcare systems.
Furthermore, we strive to deliver integrated
solutions that fit into the lives of people living
with these chronic illnesses, enabling better
disease management, better outcomes
and reduced costs.
We deliver innovative Diabetes
care solutions to people
worldwide by benefiting from
a global commercial and
industrial footprint in this area.
Disease modification in T1D and T2D
• Beta cell replacement
• Immune intervention in T1D
• Beta cell regeneration and protection
• Insulin sensitizers
Obesity
• GI and multi-agonist peptides
• Oral weight management
• Obesity devices
Translational research
• New cardio-metabolic targets
• Predictive biomarkers
Complications
• Cardiovascular risk in diabetes patients
• NASH
• Diabetic kidney disease
• Diabetic neuropathy
Insulins and Peptides
• Glucose sensing insulin
• Small molecule oral GLP-1
• Metabolic peptides with novel MOA
Drug Delivery
• Oral delivery for insulin and peptides
• Device technology
5 — PARTNERING WITH SANOFI
Diabetes & Cardiovascular
CardiovascularCardiovascular disease is the number one cause
of death globally, accounting for nearly 30%
of all deaths.
We have significant experience from
the development of innovative brands in
this therapeutic area and we remain committed
to developing new therapies by building on
our strong legacy.
We launched Praluent®
(alirocumab), an innovative
treatment helping adult patients
with hypercholesterolemia
to reduce their level of bad
cholesterol, result of our
collaboration with Regeneron.
Cardiomyopathies
• Hypertrophic Cardiomyopathy
• Dilated Cardiomyopathy
• Other forms of Cardiomyopathy
Heart Failure
• Acute Heart Failure.
• Chronic Heart Failure with Reduced
Ejection Fraction (HFrEF)
• Chronic Heart Failure with Preserved
Ejection Fraction (HFpEF)
Hyperlipidemia
• Orally bioavailable PCSK9 inhibitor and
novel oral drugs to lower LDL-C
• Oral or injectable agents for other lipid
disorders, such as high Lp(a) and
hypertriglyceridemia
• Specific therapies for diabetes-related
cardiovascular disease
Vascular Disease
• Peripheral Arterial Disease, including
critical limb ischemia and intermittent
claudication
• Microvascular disease
6 — PARTNERING WITH SANOFI
Sanofi Genzyme
Rare DiseasesFor over three decades we have discovered
and developed transformative therapies
for people with rare and special unmet
medical needs.
Our focus is on diseases with well-defined
mechanisms and high unmet needs.
We pioneered the delivery
of transformative therapies
to people with Rare Diseases,
providing hope where there
was none before.
Metabolic/Pediatric
• Glycogen storage disorders, such as
Pompe disease
• Lysosomal storage disorders, including
those with neurometabolic manifestations
• Leukodystrophies
• Hyperaminoacidemias
• Hyperammonemias (e.g. urea cycle
disorders)
Hematology
• Amyloidoses
• Gaucher disease
• Hemophilia
Nephrology
• Alport syndrome
• Fabry disease
• Polycystic kidney disease and other
ciliopathies
Neuromuscular
• Dystrophies, such as Duchenne,
alpha-dystroglycanopathy, myotonic and
facioscapulohumeral muscular dystrophy
• Pompe disease
Pulmonary
• Cystic fibrosis
Bone
• Achondroplasia
• Osteogenesis imperfecta
Gene Therapy
• AAV capsids with improved tropism for the
CNS, liver and muscle
7 — PARTNERING WITH SANOFI
Sanofi Genzyme
Multiple Sclerosis & NeuroscienceDebilitating neurodegenerative diseases of the
central nervous system including Multiple Sclerosis,
Parkinson’s Disease, Alzheimer’s and Huntington
represent significant unmet medical need, heavily
impacting patients and their families.
Our team includes
internationally recognized
scientists in Neurology,
Rare Diseases, and
Neuroimmunology, working on
slowing neurodegeneration,
modulating neuroinflammation,
and facilitating neuroprotection,
repair and remyelination.
Multiple Sclerosis
• Immunomodulation
– Drug candidates targeting lymphocytes
with novel mechanisms of action,
with potential for high efficacy and
manageable safety
• Neuroinflammation
– Drug candidates targeting CNS
inflammatory milieu, microglia and
astrocytes
• Remyelination and Neuroprotection
– Drug candidates targeting
oligodendrocyte differentiation,
remyelination and neuroprotection
• Symptom Management
– Drug candidates targeting MS-related
cognitive and behavioral symptoms,
preferably with clinical proof of concept
Neuro Rare Diseases
• Gene replacement strategies and
therapeutics for rare monogenic
neurodegenerative diseases, including
Gaucher related Parkinson’s, Huntington
Disease, Amyotrophic Lateral Sclerosis,
neurodevelopmental disorders and
Friedreich’s ataxia
• Therapeutics and novel targets for
peripheral neuropathies including Charcot-
Marie-Tooth Disease
Neurodegeneration
• Small molecules or biologics targeting
tau or alpha-synuclein that reduce
accumulation and spread of pathology
• ApoE4 correction or lowering approaches
• Normalization of insulin resistivity
and glucose metabolism
• Therapeutics and novel targets to restore
mitochondrial function
• Small molecules targeting CNS inflammatory
milieu, microglia and astrocytes
Translational Neuroscience and technologies
• Biomarkers to predict disease progression,
stratify patient populations, monitor
therapeutic interventions
• PET ligands for misfolded proteins,
neuroinflammation, and to demonstrate
therapeutic target engagement
• Methods for quantifying synaptic plasticity
and synaptic loss, neuroprotection,
or assessing remyelination in vivo
• AAV capsids for systemic or intrathecal
administration, widespread transduction of
brain cell types
• Methods of enhancing transit of
therapeutics across the Blood-Brain Barrier
8 — PARTNERING WITH SANOFI
Sanofi Genzyme
ImmunologyWe seek new therapeutics to normalize immune
responses in immune-mediated disorders
such as rheumatic, respiratory, inflammatory
skin and gastrointestinal diseases.
Our focus is on biologics, small molecules
and nucleic acid-based approaches.
We launched Dupixent®
(dupilumab), a first-in-class
biologic drug in allergic
dermatological and pulmonary
disorders, result of our
collaboration with Regeneron.
Dermatological and Pulmonary Disorders
• Atopic dermatitis
• Psoriasis
• Severe asthma
• Chronic rhinosinusitis
• Idiopathic pulmonary fibrosis
• Chronic Obstructive Pulmonary Disorder
(COPD)
• Scleroderma
Rheumatological Disorders
• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Systemic Lupus Erythematosus
Gastrointestinal Disorders
• Eosinophilic esophagitis
• Inflammatory Bowel Disease
(Crohn’s Disease, ulcerative colitis)
Novel approaches for modulation of the immune response in Autoimmune Disease
• Normalization of aberrant immune
responses in allergic disease,
including “atopic march”
Technologies to increase mechanistic understanding of Autoimmune Disease
• Identification, characterization
and validation of biomarkers
for patient stratification and monitoring
of clinical responses
9 — PARTNERING WITH SANOFI
OncologyCancer remains a leading cause of death
worldwide.
We are building on our strong heritage
in oncology research to pursue curative
approaches.
Collaborations focusing on novel therapeutic
approaches are a key part of our strategy.
We are rebuilding a competitive
position in Oncology through
a range of innovative
collaborations in the emerging
fields of immuno-oncology
and targeted therapies.
Overcoming Immunosuppression
• Modulation of immunosuppressive
components in the tumor
microenvironment
• Suppressive mechanisms within myeloid
lineage cell types
• T cell invasion and expansion Modalities
outside “classical” immune checkpoints
Cancer dependency related therapies
• Drugs or novel targets targeting:
– K-RAS directly or cancers where K-RAS
is implicated
– Oncogenic drivers and pathways
currently lacking therapy
– Co-dependency or synthetic lethality
• CRISPR/CAS9 based target identification
platform
• Targeted therapy resistance (induced
or intrinsic)
• Novel lineage targets and drugs targeting
them
Active Immunization and Antibody directed Tumor Targeting
• Stimulation of functional activity of antigen
presenting cells
• Redirection of immunity against tumors
using cell engagers & immuno-conjugates
• Innovative PRRs (pattern recognition
receptors) agonists and adjuvants
• Devices for direct intra-tumoral/intra-nodal
injection
Other Interests
• Translational Medicine and biomarkers
to support pipeline
• Immune profiling methodologies in
preclinical and clinic (immuno-monitoring).
• Novel-novel combinations
• Preclinical platform to test and validate
immuno-oncology combinations
• Molecular entities with potential
for transformative benefits
• Commercial opportunities synergistic with
current portfolio: prostate cancer, colorectal
cancer, gastric cancer, Multiple Myeloma,
TNBC (triple negative breast cancer),
NSCLCs (non-small cell lung cancer)
Sanofi Genzyme
10 — PARTNERING WITH SANOFI
Sanofi Pasteur
VaccinesAs a world leader in the field of prevention,
we offer a broad range of vaccines protecting
against 21 infectious diseases.
Our focus is on developing safe and effective
vaccines with a single or combined target against
complex diseases.
We provide more than 1 billion
doses of Vaccines each year,
making it possible to immunize
more than 500 million people
across the globe.
Vaccines, Monoclonal Antibodies & Supporting Technologies
• Novel antigens and methods for antigen
discovery
• Novel conjugation technologies.
• Vaccine vectors suitable for nasal
or oral use
• New ways to administer vaccines
Tools for improving Vaccine and Monoclonal Antibody research, development and production
• Genomics and proteomics technologies
• Prokaryotic or eukaryotic cell lines for
antigen production
• Fermentor and bioreactor technology
• Disposable systems
• Downstream processing
• Process automation
• Preservatives and stabilizers
• Bioinformatics techniques
Vaccine immune responses’ Enhancers
• Adjuvants and immunomodulators
• Vaccine vectors and delivery systems
• Biological and immunological studies
to further characterize adjuvants and
immunomodulators
Characterization and assay of immune responses and Disease Markers
• Animal models of human diseases
• In vitro models of human tissues, including
the immune system
• Biological markers
11 — PARTNERING WITH SANOFI
Infectious Diseases
Infectious DiseasesOur focus is on game-changing, breakthrough
innovations in areas of highest medical need
such as severe bacterial and parasitic infections
as well as acute and chronic viral infections.
We have a rich history in
the area of Infectious Diseases
and have signed the Davos
declaration with other leading
international companies to take
comprehensive action against
drug-resistant infections.
Products
• Antiviral agents against HBV, HIV,
and respiratory viruses
• Anti gram-negative antibiotics, potentially
with a new MoA for severe infections
• Tuberculosis or Malaria agents,
with potential for contributing
to affordable regimens and addressing
resistance issues
• Immunomodulation, anti-virulence agents
• Agents could be innovative small
molecules, biologics or natural products
Targets
• Immunomodulation, anti-virulence
approaches
• Novel bacterial or viral targets relevant
for disease resolution
Technologies
• Innovative approaches (whole cell
screenings, high content,
chemonomics…) for identification
of new antimicrobial agents
12 — PARTNERING WITH SANOFI
Platforms
Drug Discovery & BiologicsDrug Discovery identifies bioactive synthetic
molecules and advance them to the clinic.
Drug Discovey covers fields such as lead
generation biology, structural biology,
computational design, medicinal chemistry and
pharmacokinetics.
Biologics research, develop and manufacture
recombinant enzymes, mAbs, antibody-drug
conjugates, insulins, fusion proteins, gene
and nucleic acid therapeutics.
Biologics molecules make up more than 50%
of Sanofi’s development pipeline.
Drug Discovery– Next generation screening techniques
– Innovative chemical matter: small molecules,
peptides, macrocycles, natural products
– Target validation: gene editing, compound
de-orphaning technologies
– Advances in computational chemistry and
structural biology
– Novel drug delivery
– Prediction of stability, toxicity and
pharmacokinetics in silico, in vitro or in vivo
– Disease relevant 3D tissue cultures
– Systems biology/pharmacology/toxicology
models
– Identification of drug efficacy biomarkers
– Target engagement in living systems
Biologics
• Monoclonal Antibodies and
Alternative Scaffolds
– Technologies and platforms to improve the
generation and manufacturing of bi- and
multispecifics mAbs and cell engagers
– New technologies for mAb optimization,
(i.e. Fc engineering, enhancing antibody
valency, improving developability, viscosity
reduction, extending half-life)
– Novel and future biologics: non-mAbs
scaffolds, modular biologics, advanced
structure based design, synthetic biologics
– Prediction of immunogenicity and biophysical
liabilities: aggregation, high viscosity, etc
• Delivery
– Tissue-specific delivery of nucleic acid
– Therapeutics to organs other than liver
– Alternatives to GalNac ligand for
liver targeting
– Targeting
– Cell penetrating biologics, mAbs
and protein therapeutics
– Therapeutics
– Delivery of biologics across physiological
barriers: BBB, GI, skin, lungs
• Development and Manufacturing
– Improving biophysical properties of mAbs:
aggregation, viscosity, syringeability,
solubility, etc.
– Mammalian cell technologies to improve
expression and production of recombinant
proteins
– Predictive tools for biomanufacturing:
behavior under process conditions, process
simulation, technologies for online analysis
and process controls for production of
biologicals breakthrough technologies in
protein purification, e.g. column free
downstream processing
– Production of AAV-based gene therapies,
especially expression and packaging
We remain on the cutting edge
of discovery, development and
manufacturing by incorporating
external innovation into our
internal platforms.
13 — PARTNERING WITH SANOFI
Platforms
DigitalWe believe digital will transform the way therapies
are discovered, developed, and brought to
patients, providers, and payers.
Additionally, digital solutions represent new ways
of improving care at a reduced cost with improved
patient/consumer experience.
In particular for Diabetes, integrated care solutions
can bring critical enablers together and empower
people to live the life they want with better care
quality and outcomes.
We seek partners who believe in our ambition,
our global reach, our deep scientific expertise
and our commercial expertise.
We are a leader in Digital
health solutions, partnering with
companies like Science 37,
Verily Life Sciences, and Voluntis.
Drug Discovery and Development
• Distributed studies
• Patient recruitment/engagement
• Wearable sensors
• Optimizing site selection and/or
study start-up
• Decision support and visibility tools
Multichannel Engagement through Drugs plus Digital Solutions
• Patient engagement
• Medication management
• Patient, clinical, population health
decision support tools
• Coaching, nursing support
• Disease management
• Telemedicine
• Wearable sensors, connected devices
Data & Analytics from R&D to RWE (Real World Evidence)
• Target identification and disease
understanding
• Integrated laboratory solutions
• Predictive modeling
• ETL stack/infrastructure
• Patient stratification
• Drug selection/precision medicine
Diabetes Integrated Care
• Drug delivery devices; connectivity
solutions
• Innovative glucose monitoring solutions
• Decision support solutions for patients,
healthcare professionals and payers
(e.g. titration, treatment adherence,
medical algorithms)
• Behavior and food monitoring
and coaching solutions
• Digital engagement solutions, enrollment
solutions
CHC 360º Health Management
• Technologies that encourage healthier
habits, allow self-monitoring and provide
personalized recommendations, especially
for products in our core categories
– New tools for diagnosis, data-collection,
self-monitoring and adherence to therapy
– Digital Healthcare solutions for a closer
interaction with the consumer
– Solutions to provide tailor-made
recommendations considering individual
consumer needs
14 — PARTNERING WITH SANOFI
GEM
Mature Markets
• Opportunities to enhance our existing
franchises, through addition of innovative
late stage or commercial products or
acquisition of complementary established
products
Emerging Markets
• Late stage or commercialized products
that complement our broad portfolio
General Medicines & Emerging MarketsWe manage established products and generics
globally as well as innovative pharma products
in Emerging Markets.
Emerging Markets are all those outside the Mature
Markets of North America, Europe, Japan,
Australia, New Zealand and South Korea and
are divided into five Regions: Latin America, China,
Africa, Eurasia & Middle East and South Asia.
Our set of capabilities as a global biopharma
company combined with an unparalleled
footprint in Emerging Markets makes us
the partner of choice.
We can offer flexible deal terms to accommodate
our partners’ strategic needs. Leadership in Emerging Markets
• Leading franchises in Diabetes & Cardiovascular,
Thrombosis, CNS, Anti-Infectives and Specialty
Care (especially in Rare Diseases)
• One Stop Shop: Strong footprint across all key
Emerging Markets
• Integrated capabilities: R&D, Medical,
Regulatory, Market Access, Sales & Marketing
• Local manufacturing, packaging and distribution
We have an impressive presence
in Emerging Markets as a result
of decades of commitment to their
diverse needs.
15 — PARTNERING WITH SANOFI
Consumer HealthcareOur ambition is to become the best global
Consumer Healthcare business embracing
transformative healthcare solutions and
technologies.
We are among the top global
players in Consumer Healthcare,
providing new and compelling
product choices to people.
Core Categories and Adjacent Subcategories
• Differentiated, consumer relevant
innovations that have a significant growth
potential in our core categories: Cough &
Cold and Allergy, Digestive Health,
Nutritionals and Pain (including pediatric
solutions)
– Licensing and/or R&D collaborations for
consumer solutions that address relevant
needs and provide differentiated and
superior claims
– Licensing, distribution or acquisition deals
for distinctive brands and products on a
global, regional or local level which
broaden or strengthen our offer to
consumers
– Specific partnering options for superior
consumer solutions adjacent to our core
categories, including mobility, sleep and
liver health
White spaces
• Great choices outside our core categories
to enter and shape consumer relevant
categories with strong growth perspectives
– Access to Rx-to-OTC switch candidates
including first-in class switch candidates
to address unmet consumer needs
– Access to superior clinically proven
compounds including generic Rx-to-OTC
switch candidates and products that allow
addressing unmet consumer needs
– Licensing, distribution or acquisition deals
for distinctive brands and products on
a global, regional or local level which
enlarge our presence in attractive
markets and categories without current
significant footprint
CHC
16 — PARTNERING WITH SANOFI
Partnering Capabilities
Changing the Ways Sanofi Partners
Partnering Model
Pushing for Innovation
More than
16,000employees
committed to R&D
15.3%of company sales invested
in R&D, increasing
annual R&D investments
up to €6 bn by 2020
46projects in the R&D pipeline, as of April 2017
Between 2015-2020
6major innovations inDengue, Cardiovascular,Diabetes, Rheumatoid Arthritis, Atopic Dermatitis, Asthma
83industrial sites
Approximately
40,000industrial employees
Approximately
€3 bninvested over
three years
Cutting-edge Manufacturing Network
Producing
BiologicsPills/ChemistryDelivery Devices
2015-2020
Strategic Roadmap
To create long-term value
New Organizational Model
To drive focus
and simplification
Accelerate Business
Development and Strategic
Alliances activities
Strengthen and
grow the portfolio
17 — PARTNERING WITH SANOFI
• Licensing, Collaborations and M&A
• Target products and technologies supportive to R&D
• Early to late stage technology/products
The corporate partnering arm of Sanofi invests in opportunities in alignment with Sanofi’s
strategic priorities to maximize value creation. Our objective is to seek and execute
external growth and collaboration opportunities to reshape our portfolio and support
R&D innovation. Business Development & Licensing has global scope, across all business
units and therapeutic areas.
Business Development & Licensing has the flexibility to pursue a broad range of deal
structures to support the strategic intent of the partnership; from in- and out-licensing,
R&D collaborations and M&A (asset/company acquisitions and divestitures) to models
such as joint ventures, commercial collaborations and other types of strategic alliances.
• Straight equity participation
• Early stage technologies/products
• Strategic interest
The corporate venture capital arm of Sanofi invests in early stage healthcare companies
with promising new products and technologies of strategic interest to Sanofi. As a
strategic partner, Ventures invests globally and directly in innovative start-ups aligned
with Sanofi’s areas of interests, including rare genetic diseases, vaccines, transformative
therapies addressing other unmet medical needs, and digital health and other
breakthrough therapies. Ventures has an expedited decision-making process enabling
rapid and clear decisions.
In addition to equity financing, Ventures provides strategic and technical input by
leveraging the established expertise of Sanofi teams in science, preclinical and
clinical development and regulatory strategy when helpful. Ventures’ success is driven
by our ability to invest in areas where we have a unique voice and insight, and then
to engage actively, what could lead to future strategic collaborations and product
opportunities.
• Company co-creation
• Equity participation and first partner
• Deal size tailored to R&D plan
Sanofi’s company co-creation and incubation vehicle has a primary goal of
accelerating the delivery of transformative treatments to patients in need while adding
innovative products to the Sanofi pipeline. Sunrise partners for innovations that are best
developed through focused efforts by entrepreneurs in new start-up biotech companies,
and works across all therapeutic areas. Sunrise seeks programs based on novel
biological insights and the typical stage of the product opportunities at time of initial
investment is 2-4 years to IND.
Sunrise is both an equity investor and a collaborative partner, taking a risk-sharing,
science-driven investment approach captured in a jointly developed research and
development plan. Direct Sunrise investment in the company focuses on aligned interests
of all involved parties. Through Sunrise, Sanofi secures product rights, but notably the
new company retains significant rights and independent value creation opportunities.
Sanofi’s strategic interests, supported by strong internal sponsorship, drive a close
partnership with the entrepreneurs. Further, Sunrise bridges innovative science with
expert capabilities and committed resources from Sanofi. Our close and collaborative
relationship provides important validation to any nascent life sciences company.
Partnering Model
Deal Making Flexibility
18 — PARTNERING WITH SANOFI
Value Creation through Partnerships
Alliance Management
We believe that Alliance Management is the keystone of any sound and successful collaboration.
For this reason, we have a dedicated team of Alliance Managers, working across the globe to fulfill
the mission of maximizing the value through collaborative engagement, management of risk, actionable
assessment and agile governance.
19 — PARTNERING WITH SANOFI
Diabetes & Cardiovascular
Onduo – Verily
Joint venture created through Sanofi and Verily’s
diabetes-focused collaboration to develop a
comprehensive diabetes management platform.
Onduo’s mission is to help people with diabetes
live full, healthy lives by developing comprehensive
solutions that combine devices, software,
medicine, and professional care to enable simple
and intelligent disease management.
The company will leverage Verily’s experience in
miniaturized electronics, analytics, and consumer
software development, and Sanofi’s clinical
expertise and experience in bringing innovative
treatments to people living with diabetes.
Lexicon Pharmaceuticals
Collaboration and license agreement in diabetes on
sotagliflozin, and investigational new oral medicine
in phase III studies for patients with diabetes.
MyoKardia
Worldwide collaboration to discover and develop
first-of-its-kind targeted therapeutics for heritable
heart diseases known as cardiomyopathies, the
most common forms of heart muscle disease. The
collaboration builds upon MyoKardia’s pioneering
science, which hopes to correct the disruptive effects
that disease mutations have on heart muscle
contraction.
Sanofi Pasteur (Vaccines)
MedImmune
Agreement to develop and commercialize a
monoclonal antibody (MEDI8897) for the
prevention of Respiratory Syncytial Virus (RSV)
associated illness in newborns and infants.
Walter Reed Army Institute of Research (WRAIR)
Cooperative Research and Development
Agreement (CRADA) for the technology to
advance WRAIR’s Zika purified, inactivated virus
(ZPIV) vaccine.
General Medicines & Emerging
Markets
JHL Biotech
Collaboration for the development and
commercialization of biological therapeutics in
China and with potential international expansion.
Consumer Healthcare
CR Pharmaceutical
Strategic alliance to explore consumer healthcare
opportunities in China.
Sanofi Genzyme (Specialty Care)
ImmuNext
Agreement focused on the development of a
novel CD40L monoclonal antibody (INX-021)
with the potential to treat a range of autoimmune
diseases including Lupus and Multiple Sclerosis.
Alnylam
Collaboration in rare diseases to develop and
commercialize RNAi therapeutics targeting
transthyretin (TTR) for the treatment of transthyretin-
mediated amyloidosis (ATTR) in Japan and other
Asia-Pacific countries, that has been extended in
January 2014 by forming a transformational
alliance focused on the advancement of RNAi
therapeutics as genetic medicines.
Regeneron
Since 2007, Regeneron and Sanofi have
collaborated to discover, develop, manufacture
and commercialize fully human monoclonal
antibodies. In 2015, Sanofi and Regeneron entered
into a new global collaboration in the emerging
field of immuno-oncology to discover, develop
and commercialize new antibody cancer
treatments. This long-standing, broad alliance has
enriched our pipeline with products such as
Praluent®, Dupixent®, Kevzara® and a PD-1 inhibitor.
Innate Pharma
Research collaboration and license agreement in
immuno-oncology for new biospecific antibodies
using Innate Pharma’s technology and Sanofi’s
technology and tumor targets.
BioNtech
Research collaboration and license agreement in
immuno-oncology leveraging the scientific expertise
of the two organizations to discover and develop up
to five cancer immunotherapies, each consisting of
a mixture of synthetic messenger RNAs (mRNAs).
Voyager Therapeutics
Collaboration to develop gene therapies for
neurological diseases such as Parkinson’s, Friedreich’s
ataxia and Huntington’s disease combining our
experience in the field of adeno-associated virus (AAV)
gene therapy and Voyager’s AAV product engine to
develop therapies for multiple programmes.
Platforms
Science 37
Agreement to use its MetasiteTM model and NORA®
technology for digital clinical trials to improve
recruitment and reduce trial times.
Alliance Management
20 — PARTNERING WITH SANOFI
We invite you to contact us about partnering opportunities
according to your area of interest.
Diabetes & CardiovascularLoic HAMEON – [email protected]
Diabetes: Ulrich WENDT – [email protected]
Cardiovascular: Michael DRAPER – [email protected]
Sanofi GenzymeMark BARRETT – [email protected]
Rare Diseases: Brian BRONK – [email protected]
Multiple Sclerosis & Neuroscience: Isaac VEINBERGS – [email protected]
Oncology: Kaan CERTEL – [email protected]
Immunology: Adam KEENEY – [email protected]
Sanofi PasteurJean-Louis GRUNWALD – [email protected]
Vaccines: Roman CHICZ – [email protected]
Infectious Diseases
Anne DAGALLIER – [email protected]
PlatformsDrug Discovery: Peter HAMLEY – [email protected]
Biologics: Shiv KRISHNAN – [email protected]
Digital: Rachel SHA – [email protected]
General Medicines & Emerging MarketsLatin America: Nicolas GOBEILL – [email protected]
China: Matthieu MERLIN – [email protected]
Africa, Eurasia & Middle East, South Asia: Eric SOL – [email protected]
Consumer HealthcareOliver FREICHEL – [email protected]
Contacts
Partnering Opportunities
This 2017 Sanofi document was designed and produced by the Sanofi Communications Department and .
Photo Credits:
Cover: Getty Imagebank; p. 4: Christian Fleury/Capa Pictures; p. 5: Vincent Moncorgé; p. 6: Pierre-Olivier/Capa Pictures; p. 7: Pierre-Olivier/Capa Pictures;
p. 8: Cedric Arnold/Capa Pictures; p. 9: Randy Monceaux; p. 10: Christian Fleury/Capa Pictures; p. 11: Pierre-Olivier/Capa Pictures;
p. 12: Pierre-Olivier/Capa Pictures; p. 13: Getty Imagebank; p. 14: Diego Cervo/Fotolia; p. 15: Piotr Redlinski/Capa Pictures.
Forward-Looking Statements:
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking statements are generally identified by the words ”expects”, "anticipates",
”believes”, ”intends”, ”estimates”, ”plans” and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-
looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially
from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development, future clinical data and analysis, including post-marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any
such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such
product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing
interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under ”Risk Factors” and ”Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Partnering Opportunities
For more information visit our website:
http://en.sanofi.com/partners/partners.aspx
www.sanofi.com
54, rue La Boétie
75008 Paris, France